GlassScriptPhysician profile
Yatinder Bains
NPI 1205908118
$5,141.38
in general payments reported to CMS, 2019-2025
21 companies · $427 in 2025
The $427 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $187 · 2020: $162 · 2021: $3,023 · 2022: $838 · 2023: $249 · 2024: $255 · 2025: $427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $891 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00 · Grant: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $891.17 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
| Grant | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eli Lilly and Company | $2,250.00 | 2021 | |
| Boston Scientific Corporation | $765.47 | 2020-2025 | Compliance Endokit, Spyglass, Resolution Clip |
| Genzyme Corporation | $624.01 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $280.54 | 2019-2024 | Xifaxan |
| Abbvie INC. | $246.80 | 2020-2025 | Rinvoq |
| Pfizer INC. | $188.57 | 2023-2025 | |
| Madrigal Pharmaceuticals | $139.52 | 2025 | Rezdiffra |
| Celgene Corporation | $136.81 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $117.98 | 2019-2025 | Entyvio |
| Merck Sharp & Dohme LLC | $78.89 | 2019-2021 | |
| Redhill Biopharma INC. | $43.62 | 2022-2023 | Aemcolo, Movantik, Talicia |
| Ferring Pharmaceuticals INC. | $38.32 | 2019 | |
| Olympus America INC. | $36.10 | 2019-2024 | Evis X1 Video System Center |
| Braintree Laboratories, INC. | $35.42 | 2022-2023 | Sutab |
| Laborie Medical Technologies Corp. | $35.21 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $33.81 | 2024-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $29.22 | 2021 | |
| Phathom Pharmaceuticals, INC. | $17.89 | 2025 | Voquezna |
| Capsovision, INC. | $15.34 | 2025 | Capsocam Plus |
| Intercept Pharmaceuticals, INC. | $15.00 | 2020 | |
| Shire North American Group INC | $12.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yatinder Bains listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.